Christina Herder, acting CEO of the biotechnology company Idogen, joined the BioStock studio to talk about the company's participation at the 6th Antigen-Specific Immune Tolerance Drug Development in Boston. At the conference, Idogen met with many companies and researchers in the field of immune tolerance. In addition, they were strengthened in their conviction that they are on the right track in the development of a tolerogenic cell therapy. However, the company is currently in need of capital to be able to restart the clinical study in hemophiliac patients.